Compare TNDM & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNDM | ARDX |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2013 | 2014 |
| Metric | TNDM | ARDX |
|---|---|---|
| Price | $23.56 | $6.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 9 |
| Target Price | ★ $27.05 | $14.67 |
| AVG Volume (30 Days) | 2.3M | ★ 3.8M |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,014,736,000.00 | $2,607,000.00 |
| Revenue This Year | $10.96 | $35.64 |
| Revenue Next Year | $9.33 | $34.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.93 | N/A |
| 52 Week Low | $10.00 | $3.50 |
| 52 Week High | $29.65 | $8.40 |
| Indicator | TNDM | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 48.87 |
| Support Level | $19.04 | $5.49 |
| Resistance Level | $29.65 | $8.23 |
| Average True Range (ATR) | 1.78 | 0.37 |
| MACD | 0.24 | -0.03 |
| Stochastic Oscillator | 48.99 | 63.20 |
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.